Capital Investment Advisory Services LLC Sells 1,206 Shares of AstraZeneca PLC (NASDAQ:AZN)

Capital Investment Advisory Services LLC lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 26.6% during the 4th quarter, Holdings Channel reports. The fund owned 3,321 shares of the company’s stock after selling 1,206 shares during the period. Capital Investment Advisory Services LLC’s holdings in AstraZeneca were worth $218,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the 3rd quarter worth approximately $28,000. Ashton Thomas Securities LLC purchased a new stake in AstraZeneca during the 3rd quarter worth approximately $45,000. Albion Financial Group UT increased its stake in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management raised its holdings in shares of AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after buying an additional 192 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 0.7 %

AstraZeneca stock opened at $70.76 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm has a market cap of $219.43 billion, a PE ratio of 33.86, a P/E/G ratio of 1.17 and a beta of 0.46. The stock’s 50 day simple moving average is $66.98 and its two-hundred day simple moving average is $73.97. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the business earned $0.87 earnings per share. Analysts anticipate that AstraZeneca PLC will post 4.13 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.